Small molecule - Articles - Page 108

Drug Design, Drug Delivery & Technologies

Terray Therapeutics and Bristol Myers Squibb enter multi-target collaboration

Dec. 15, 2023

Terray Therapeutics Inc. has established a multi-target collaboration agreement with Bristol Myers Squibb to discover and develop small-molecule therapeutics in certain disease areas.

Drug Design, Drug Delivery & Technologies

Prism, Eli Lilly collaborate on protein-protein interaction inhibitors

Nov. 29, 2023

Prism Biolab Co. Ltd. has entered into a drug discovery, license and collaboration agreement with Eli Lilly & Co.

Illustration demonstrating the Warburg effect

Cancer

Vidac reports in vitro results for VDA-1275 to treat solid tumors

Nov. 29, 2023

Vidac Pharma Holding plc has announced results from an in vitro study of VDA-1275 in combination with chemotherapeutic agents to treat solid tumors. VDA-1275 is a potent small molecule that reverses cancer cell hyper glycolytic metabolism (Warburg effect).

Cross section illustration of ion channel in cell membrane

Neurology/Psychiatric

New analgesic for chronic pain found among 27M compounds

Nov. 21, 2023

Researchers from New York University College of Dentistry’s Pain Research Center in collaboration with the University of Pittsburgh found a candidate for chronic pain treatment among a library of 27 million compounds.

Neurology/Psychiatric

Satellos reveals drug target, lead candidate in Duchenne program

Nov. 15, 2023

Satellos Bioscience Inc. has disclosed further information on its lead drug program in Duchenne muscular dystrophy.

Immuno-oncology

Invios and Dana-Farber to investigate INV-501 in glioblastoma

Nov. 9, 2023

Invios GmbH and Dana-Farber Cancer Institute have entered into a preclinical research collaboration to evaluate Invios' immune-activating small molecule, INV-501, as a potential treatment for glioblastoma.

Immuno-oncology

Abbisko's CD73 inhibitor ABSK-051 cleared for clinic in China

Nov. 9, 2023

Abbisko Therapeutics Co. Ltd. has received clearance from China's National Medical Products Administration (NMPA) to conduct clinical trials in China of ABSK-051, a novel small-molecule CD73 inhibitor, for advanced solid tumors.

Neurology/Psychiatric

Aquinnah reports preclinical findings with lead compound for Alzheimer's disease

Oct. 31, 2023

Aquinnah Pharmaceuticals Inc. has announced preclinical research findings for a novel small-molecule therapeutic designed to slow or stop the progression of Alzheimer's disease and related disorders.

Dermatologic

Selective BET inhibitor VYN-202 shows promise in models of psoriasis and RA

Oct. 30, 2023

Vyne Therapeutics Inc. has released promising new preclinical data on its oral small-molecule BD2-selective BET inhibitor, VYN-202, in preclinical models of psoriasis and rheumatoid arthritis. In a well-established model, a psoriasis phenotype was induced in BALB-C mice, and treatment was administered intraperitoneally with either VYN-202, the allosteric TYK2 inhibitor Sotykto (deucravacitinib, Bristol Myers Squibb Co.) or placebo.

Cancer

Erasca receives IND clearance for KRAS G12C inhibitor ERAS-3490 for solid tumors

Dec. 14, 2022

Erasca Inc. has received FDA clearance of its IND application for ERAS-3490, an orally available small-molecule KRAS G12C inhibitor designed to have high central nervous system (CNS) penetration for the treatment of KRAS G12C-mutated solid tumors, including non-small-cell lung cancer (NSCLC).